CLINICAL IMPLICATIONS OF JAK2 MUTATIONS IN MYELOPROLIFERATIVE DISORDERS

REFERENCES

• Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–66.
   PubMed Web of Science ®Google Scholar
• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372–5.
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85–109.
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–64.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. How we treat patients with polycythemia vera. Blood 2007; 109: 5104–11.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era. Hematology Am Soc Hematol Educ Program 2006: 240–5.
   Google Scholar
• Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520–30.
   PubMed Web of Science ®Google Scholar
• Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera. N Engl J Med 1974; 290: 1382.
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354: 2034–45.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–8.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–0.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97.
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–68.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
   PubMed Web of Science ®Google Scholar
• Hammond E, Shaw K, Carnley B, P’ng S, James I, Herrmann R. Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn 2007; 9: 242–8.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840–6.
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK2 mutations in polycythemia vera�molecular mechanisms and clinical applications. N Engl J Med 2007; 356: 444–5.
   PubMed Web of Science ®Google Scholar
• Remacha AF, Estivill C, Sarda MP, et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285–6.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21: 2074–5.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–53.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–6.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–9.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–13.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofi - brosis. Blood 2006; 107: 2098–100.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–8.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofi brosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–7.
   PubMed Web of Science ®Google Scholar